New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
The company has launched its new range of 25 allopathy ophthalmic products including GUERIMOD, GUERIPRED, BIMATO MST etc. for curing various diseases related to eyes
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
Subscribe To Our Newsletter & Stay Updated
